The sizable funding accelerates NEOK Bio’s entry into the competitive ADC market, potentially reshaping cancer therapy with bispecific ADCs that could offer superior outcomes. Success could validate the bispecific ADC approach and attract further investment in next‑generation oncology biologics.
Comments
Want to join the conversation?
Loading comments...